Expression and Clinical Significance of Artemin Protein in Triple-negative and Nontriple-negative Breast Cancer Tissues
-
摘要:目的
研究蛋白Artemin在三阴性（triple-negative breast cancer, TNBC）和非三阴性（non-triplenegative breast cancer, non-TNBC）乳腺癌组织中的表达情况，进一步探索蛋白Artemin与乳腺癌临床病理及预后的关系，为临床判断其生物学行为及评估预后提供有力证据。
方法回顾性分析2005年7月至2009年7月间河北医科大学附属沧州市中心医院收治的乳腺癌患者，根据入选标准，随机抽取三阴性及非三阴性乳腺癌各120例作为研究对象。运用统计学方法对所有数据进行t检验、χ2检验，生存分析采用寿命表法、Kaplan-Meier曲线，Cox比例风险模型进行检验。
结果蛋白Artemin阳性率为61.7%（148/240），在TNBC中的阳性率为82.5%（99/120），明显高于non-TNBC中的阳性率41.0%（49/120）；在TNBC组中蛋白Artemin阳性与阴性的患者1、3、5年生存率分别为93.0%、78.0%、50.0% vs. 100.0%、89.0%、79.0%；non-TNBC组中蛋白Artemin阳性与阴性的患者1、3、5年生存率分别为98.0%、89.0%、89.0% vs. 99.0%、97.0%、97.0%，差异具有统计学意义（P＜0.05）。
结论蛋白Artemin在TNBC乳腺癌中的表达明显高于non-TNBC，生存率明显降低，是判断乳腺癌恶性程度的重要指标，值得推广研究。
Abstract:ObjectiveTo investigate the expression of Artemin protein in triple-negative breast cancer (TNBC) and non-triple-negative breast cancer (non-TNBC) tissues, and to further explore its relationship with clinical pathology and the prognosis of tumor, to provide powerful evidence for judging biological behaviour and evaluating the prognosis.
MethodsAccording to the criteria, 240 cases of breast cancer (120 cases of TNBC, 120 cases of non-TNBC, respectively) were selected randomly and admitted to Cangzhou Central Hospital of Hebei Medical University from July 2005 to July 2009. The expression of Artemin was detected in tumor tissues. All data were analyzed using t test and chi-square test, and the survival of patients was analyzed using the life table and Kaplan-Meier curves. The COX proportional hazards model was also used for the prognosis.
ResultsThe positive expression rate of Artemin protein was 61.7％(148/240) . The positive rate of Artemin in TNBC tissues was higher than that in non-TNBC tissues [82.5%(99/120) vs. 41.0%(49/120) ]. The survival rates of 1-, 3-, 5-year in the groups of TNBC with positive Artemin, TNBC without Artemin, non-TNBC with positive Artemin, and non-TNBC without Artemin were 93.0%, 78.0%, 50.0% vs. 100.0%, 89.0%, 79.0% vs. 98.0%, 89.0%, 89.0% vs. 99.0%, 97.0%, 97.0%, respectively(P<0.05) .
ConclusionArtemin is clearly expressed higher in TNBC than non-TNBC tissues, and is one of the important indicators for the prognosis of breast cancer, with great value for research.
-
Key words:
- Breast cancer /
- Artemin /
- Immunohistochemistry /
- Prognosis
-
-
![]()
图 2 蛋白Artemin阳性和阴性的TNBC和non-TNBC患者生存曲线
Figure 2 Survival curves of TNBC and non-TNBC patients with positive and negative Artemin expression
表 2 影响TNBC和non-TNBC患者预后的多因素分析
Table 2 Multivariate analysis of prognosis factors for TNBC and non-TNBC patients
下载: 导出CSV
-
[1] Thike AA, Cheok PY, Jara-Lazaro AR, et al. Triple-negative breast cancer: clinicpathological characteristics and relationship with basal-like breast cancer[J]. Mod Pathol, 2010, 23(1) : 123-33.
[1] Thike AA, Cheok PY, Jara-Lazaro AR, et al. Triple-negative breast cancer: clinicpathological characteristics and relationship with basal-like breast cancer[J]. Mod Pathol, 2010, 23(1): 123-33. [2] 马睿锐, 陈琳, 陈欣, 等. 183例三阴性乳腺癌临床病理特征及生存分析[J]. 中华普通外科杂志, 2012, 27(3) : 230-3. Ma RR, Chen L, Chen X, et al. Clinicopathologic characteristics and survival analysis of 183 cases of triple negative breast cancer[J]. Zhonghua Pu Tong Wai Ke Za Zhi, 2012, 27(3) : 230-3.
[2] Ma RR, Chen L, Chen X, et al. Clinicopathologic characteristics and survival analysis of 183 cases of triple negative breast cancer[J]. Zhonghua Pu Tong Wai Ke Za Zhi, 2012, 27(3): 230-3. [马睿锐, 陈琳, 陈欣, 等. 183例三阴性乳腺癌临床病理特征及 生存分析[J]. 中华普通外科杂志, 2012, 27(3): 230-3.] [3] Banerjee A, Wu ZS, Qian P, et al. ARTEMIN synergizes with TWIST1 to promote metastasis and poor survival outcome in patients with ER negative mammary carcinoma[J]. Breast Cancer Res, 2011, 13(6) : R112.
[3] Banerjee A, Wu ZS, Qian P, et al. ARTEMIN synergizes with TWIST1 to promote metastasis and poor survival outcome in patients with ER negative mammary carcinoma[J]. Breast Cancer Res, 2011, 13(6): R112. [4] Goldhirsch A, Wood WC, Coates AS, et al．Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J]. Ann Oncol, 2011, 22(8): 17 36-47. [4] Goldhirsch A, Wood WC, Coates AS, et al．Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J]. Ann Oncol, 2011, 22(8) : 1736-47.
[5] Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM[J]. Ann Surg Oncol, 2010, 17(6): 1471-4. [5] Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM[J]. Ann Surg Oncol, 2010, 17(6) : 1471-4.
[6] Zhang Rui, Chen HJ, Wei B, et al. Reproducibility of the Nottingham modification of the Scarff-Bloom-Richardson histological grading system and the complimentary value of Ki-67 to the system[J]. Chin Med J (Engl), 2013, 123(15) : 1976-82.
[6] Zhang Rui, Chen HJ, Wei B, et al. Reproducibility of the Nottingham modification of the Scarff-Bloom-Richardson histological grading system and the complimentary value of Ki-67 to the system[J]. Chin Med J (Engl), 2013, 123(15): 1976-82. [7] Gao BY, Liu Y, Xia LP, et al. Comparison of clinicopathological features and prognosis in triple-negative and non triple·-negative breast cancer[J]. Zhong Liu Fang Zhi Yan Jiu, 2013, 40(8): 786-8. [高炳玉, 刘玉, 夏立平, 等. 三阴性乳腺癌和非三阴性乳腺癌 临床特征及预后的比较分析[J]. 肿瘤防治研究, 2013, 40(8): 78 6-8.] [7] 高炳玉, 刘玉, 夏立平, 等. 三阴性乳腺癌和非三阴性乳腺癌临床特征及预后的比较分析[J]. 肿瘤防治研究, 2013, 40(8) : 786-8. Gao BY, Liu Y, Xia LP, et al. Comparison of clinicopathological features and prognosis in triple-negative and non triple·-negative breast cancer[J]. Zhong Liu Fang Zhi Yan Jiu, 2013, 40(8) : 786-8.
[8] 张庆慧, 徐嘉雯. 提高对基底细胞样乳腺癌和三阴性乳腺癌的认识[J]. 临床与实验病理学杂志, 2008, 24(2) : 131-6. Zhang QH, Xu JW. Increase the consensus of the basal cells breast cancer and three negative breast cancer[J]. Lin Chuang Yu Shi Yan Bing Li Xue Za Zhi, 2008, 24(2) : 131-6.
[8] Zhang QH, Xu JW. Increase the consensus of the basal cells breast cancer and three negative breast cancer[J]. Lin Chuang Yu Shi Yan Bing Li Xue Za Zhi, 2008, 24(2): 131-6. [张庆慧, 徐嘉雯. 提 高对基底细胞样乳腺癌和三阴性乳腺癌的认识[J]. 临床与实验 病理学杂志, 2008, 24(2): 131-6.] [9] Meng LX, Chi YH, Wang XX, et al. Neurotrophic artemin promotes motility and invasiveness of MIA PaCa-2 pancreatic cancer cells[J]. Asian Pac J Cancer Prev, 2012, 13(5): 1793-7. [9] Meng LX, Chi YH, Wang XX, et al. Neurotrophic artemin promotes motility and invasiveness of MIA PaCa-2 pancreatic cancer cells[J]. Asian Pac J Cancer Prev, 2012, 13(5) : 1793-7.
[10] Banerjee A, Wu ZS, Qian PX, et al. ARTEMIN promotes de novo angiogenesis in ER negative mammary carcinoma through activation of TWIST1-VEGF-A signaling[J]. PLoS One, 2012, 7(11) : e50098.
[10] Banerjee A, Wu ZS, Qian PX, et al. ARTEMIN promotes de novo angiogenesis in ER negative mammary carcinoma through activation of TWIST1-VEGF-A signaling[J]. PLoS One, 2012, 7( 11): e50098. [12] Li CY, Wang P, Zhang S, et al. Clinicopathological features and prognosis of triple-negative breast cancer[J]. Zhonghua Zhong Liu Za Zhi, 2013, 35(6) : 463-7.
[12] Li CY, Wang P, Zhang S, et al. Clinicopathological features and prognosis of triple-negative breast cancer[J]. Zhonghua Zhong Liu Za Zhi, 2013, 35(6): 463-7. [李春艳, 王培, 张晟, 等. 三阴性乳腺 癌的临床病理特征和预后分析[J]. 中华肿瘤杂志, 2013, 35(6): 46 3-7.] [13] Chu J. Clinicopathological features and prognosis factors of triplenegative breast cancer[J]. Xian Dai Zhong Liu Xue, 2011, 19(5) : 921-4. 李春艳, 王培, 张晟, 等. 三阴性乳腺癌的临床病理特征和预后分析[J]. 中华肿瘤杂志, 2013, 35(6) : 463-7.
[14] Qiu JD, Ma ZH, Ma JH, et al. Comparison of clinicopathological features and prognosis in triple-negative and non triple-negative breast cancer[J]. Zhonghua Nei Fen Mi Wai Ke Za Zhi, 2012, 6(5) : 313-7. 储君. 三阴性乳腺癌的临床病理特征及预后因素分[J]. 现代肿瘤医学, 2011, 19(5) : 921-4.
[13] Chu J. Clinicopathological features and prognosis factors of triplenegative breast cancer[J]. Xian Dai Zhong Liu Xue, 2011, 19(5): 92 1-4. [储君. 三阴性乳腺癌的临床病理特征及预后因素分[J]. 现代肿瘤医学, 2011, 19(5): 921-4.] [14] Qiu JD, Ma ZH, Ma JH, et al. Comparison of clinicopathological features and prognosis in triple-negative and non triple-negative breast cancer[J]. Zhonghua Nei Fen Mi Wai Ke Za Zhi, 2012, 6( 5): 313-7. [邱镜丹, 马振海, 马金辉, 等. 三阴与非三阴性乳 腺癌临床病理特征与预后比较[J]. 中华内分泌外科杂志, 2012, 6( 5): 313-7.] [15] Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007, 13(15Pt1) : 4429-34. 邱镜丹, 马振海, 马金辉, 等. 三阴与非三阴性乳腺癌临床病理特征与预后比较[J]. 中华内分泌外科杂志, 2012, 6(5) : 313-7.
[15] Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007, 13(15Pt1): 4429-34.
计量
- 文章访问数: 1114
- HTML全文浏览量: 288
- PDF下载量: 311
